Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
Sign Up to like & getrecommendations! Published in 2022 at "Pathology and Oncology Research"
DOI: 10.3389/pore.2022.1610276
Abstract: Despite the introduction of novel agents, multiple myeloma remains incurable for most patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor, had shown promising results in patients with translocation t(11;14), but questions remain open… read more here.
Keywords: venetoclax therapy; myeloma; targeted venetoclax; multiple myeloma ... See more keywords